Literature DB >> 31285670

Measuring colposcopy quality in Canada: development of population-based indicators.

K Decker1,2, N Baines3, C Muzyka4, M Lee5, M H Mayrand6, H Yang7, S Fung3, D Mercer8, S McFaul9, R Kupets10, R Savoie11, R Lotocki12, J Bentley13.   

Abstract

Background: Colposcopy is a key part of cervical cancer control. As cervical cancer screening and prevention strategies evolve, monitoring colposcopy performance will become even more critical. In the present paper, we describe population-based colposcopy quality indicators that are recommended for ongoing measurement by cervical cancer screening programs in Canada.
Methods: The Pan-Canadian Cervical Cancer Screening Network established a multidisciplinary expert working group to identify population-based colposcopy quality indicators. A systematic literature review was conducted to ascertain existing population and program-level colposcopy quality indicators. A systems-level cervical cancer screening pathway describing each step from an abnormal screening test, to colposcopy, and back to screening was developed. Indicators from the literature were assigned a place on the pathway to ensure that all steps were measured. A prioritization matrix scoring system was used to score each indicator based on predetermined criteria. Proposed colposcopy quality indicators were shared with provincial and territorial screening programs and subsequently revised.
Results: The 10 population-based colposcopy quality indicators identified as priorities were colposcopy uptake, histologic investigation (biopsy) rate, colposcopy referral rate, failure to attend colposcopy, treatment frequency in women 18-24 years of age, re-treatment proportion, colposcopy exit-test proportion, histologic investigation (biopsy) frequency after low-grade Pap test results, length of colposcopy episode of care, and operating room treatment rate. Two descriptive indicators were also identified: colposcopist volume and number of colposcopists per capita. Summary: High-quality colposcopy services are an essential component of provincial cervical cancer screening programs. The proposed quality and descriptive indicators will permit colposcopy outcomes to be compared between provinces and across Canada so as to identify opportunities for improving colposcopy services.

Entities:  

Keywords:  Colposcopy; mass screening; quality of health care

Year:  2019        PMID: 31285670      PMCID: PMC6588076          DOI: 10.3747/co.26.4709

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  10 in total

1.  Use of the prioritization matrix to enhance triage algorithms in clinical decision support software.

Authors:  Frederick North; Prathibha Varkey
Journal:  Am J Med Qual       Date:  2010-10-08       Impact factor: 1.852

2.  The importance of population-based performance measures.

Authors:  Joseph S Ross; Albert L Siu
Journal:  Health Serv Res       Date:  2007-02       Impact factor: 3.402

3.  Colposcopic episodes of care: referral, treatment, follow-up, and exit patterns of care for women with abnormal pap smears.

Authors:  Rachel Kupets; Yan Lu; Danielle Vicus; Lawrence Paszat
Journal:  J Obstet Gynaecol Can       Date:  2014-12

4.  Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Charles Wibbelsman; Teresa M Darragh; Adaleen Powers; Sepideh Farhat; Stephen Shiboski
Journal:  Obstet Gynecol       Date:  2010-12       Impact factor: 7.661

5.  Performance measures related to colposcopy for canadian cervical cancer screening programs: identifying areas for improvement.

Authors:  Kathleen M Decker; C Meg McLachlin; Robert Lotocki
Journal:  J Obstet Gynaecol Can       Date:  2015-03

6.  Colposcopic management of abnormal cervical cytology and histology.

Authors:  James Bentley
Journal:  J Obstet Gynaecol Can       Date:  2012-12

7.  Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.

Authors:  Gina Suzanne Ogilvie; Dirk van Niekerk; Mel Krajden; Laurie W Smith; Darrel Cook; Lovedeep Gondara; Kathy Ceballos; David Quinlan; Marette Lee; Ruth Elwood Martin; Laura Gentile; Stuart Peacock; Gavin C E Stuart; Eduardo L Franco; Andrew J Coldman
Journal:  JAMA       Date:  2018-07-03       Impact factor: 56.272

8.  HPV testing with cytology triage for cervical cancer screening in routine practice.

Authors:  Karolina Louvanto; Myriam Chevarie-Davis; Agnihotram Venkata Ramanakumar; Eduardo Luis Franco; Alex Ferenczy
Journal:  Am J Obstet Gynecol       Date:  2013-12-25       Impact factor: 8.661

9.  Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study.

Authors:  M E Cruickshank; J Pan; S C Cotton; K Kavanagh; C Robertson; K Cuschieri; H Cubie; T Palmer; K G Pollock
Journal:  BJOG       Date:  2017-03-09       Impact factor: 6.531

10.  Benefit of cervical screening at different ages: evidence from the UK audit of screening histories.

Authors:  P Sasieni; J Adams; J Cuzick
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.